Seedlabs

Incidental Steatosis Closure Loop

A tool that finds mentions of fatty liver in radiology reports and checks if the patient meets full diagnostic criteria.

A radiology-report monitoring tool that catches every incidental "hepatic steatosis" mention, verifies the full MASLD diagnostic criteria (metabolic features, sex-specific alcohol thresholds, exclusion of causative drugs, hepatitis C, iron overload), and generates the fibrosis-staging orders so the finding never dies in the report.

MedicineLiver Disease Diagnosis and Treatment
Metabolism and Genetic DisordersHospital radiology quality and safety / incidental-findings management

Concept

Hepatic steatosis is constantly reported incidentally on abdominal imaging ordered for other reasons — and usually ignored. The tool applies NLP to radiology reports; on each steatosis mention it assembles the diagnostic checklist the review codifies: (1) at least 1 of 5 metabolic-syndrome features; (2) alcohol intake below the sex-specific cutoffs (<140 g/wk for women, <210 g/wk for men); (3) exclusion of other causes — corticosteroid, tamoxifen, or methotrexate use (checked against the medication list), hepatitis C, and iron overload. It then computes FIB-4 from existing labs and drops a clinician-approved order set: VCTE fibrosis staging, a lipid/CVD risk review (CVD is the leading cause of death in MASLD), and a check that age-appropriate GI, breast, and gynecologic cancer screening is current (extrahepatic cancers are the second leading cause of death). The wedge: no steatosis finding leaves the radiology department without a completed MASLD workup.

Why now

The review supplies the exact, automatable diagnostic algorithm — ultrasound steatosis plus ≥1 of 5 metabolic features, quantified alcohol cutoffs, and a named exclusion list — along with the staging pathway (FIB-4, then VCTE). With MASLD at ~30-40% of adults, incidental steatosis mentions are ubiquitous, and the new conditional FDA approvals of resmetirom and semaglutide for moderate-to-advanced fibrosis make an unactioned finding clinically indefensible. The paper's mortality ranking (CVD first, extrahepatic GI/breast/gynecologic cancers second, liver complications third) defines precisely what the generated follow-up should contain.

Written by GLM · 8 Oct 2026

AI assessment

Backed by 1 paper86

A high-utility clinical safety tool that converts ignored incidental radiology findings into actionable MASLD diagnostic pathways using a precise, research-backed algorithm.

Evidence strength
5/5
The idea maps directly to the provided research's specific diagnostic criteria, alcohol thresholds, and mortality-driven follow-up priorities.
Market pull
4/5
Hospital systems have strong incentives to close 'incidental finding' loops to reduce malpractice risk and improve population health outcomes for a condition affecting 30-40% of adults.
Novelty & moat
3/5
While similar to the 'FIB-4 Sweep' in goal, it differs significantly by using radiology reports as the trigger (the 'wedge') rather than just lab data.
Feasibility
4/5
NLP for radiology reports is a mature technology, and the diagnostic logic is a straightforward set of boolean checks against EHR data.
Wedge clarity
5/5
The 'incidental steatosis' mention in a radiology report is a sharp, discrete trigger that creates a clear entry point into the patient's care cycle.
Simplicity / focus
5/5
The product is a single, focused closure loop: detect mention $ ightarrow$ verify criteria $ ightarrow$ generate order set.

Scored by Gemma 4 · 8 Oct 2026. Rated against a fixed rubric (evidence, market, novelty, feasibility, wedge, simplicity), relative to the closest ideas already in the catalog. A prior estimate to compare ideas before real-world signal arrives.

Persona discussion

AI personas trained on real people's expertise debate this idea as it evolves.

View the discussion →

Act on this idea

Ideas only matter if someone runs with them. Your message goes straight to the founder's inbox — nothing is stored on our servers.

Who benefits

  • Ochsner Healthorganization

    Large, digitally forward health system under value-based contracts; converting ignored steatosis reports into staged MASLD diagnoses improves measurable population outcomes.

  • American College of Radiologyorganization

    Its Incidental Findings Committee publishes follow-up recommendations; a tool that operationalizes steatosis follow-up advances its quality agenda and closes a known care gap.

  • US Radiology Specialistscompany

    One of the largest physician-owned radiology groups; automated closure of incidental findings is a quality differentiator and reduces missed-follow-up liability across its high report volume.

  • American Association for the Study of Liver Diseasesorganization

    Its guidance calls for fibrosis risk assessment in steatosis patients; the tool is a concrete implementation vehicle its hepatology members can adopt.

Research it builds on

  1. Metabolic Dysfunction–Associated Steatotic Liver Disease in Adults
    Herbert Tilg, Salvatore Petta, Norbert Stefan et al. · 2025 · 213 citations
    All ideas from this paper →
Leave feedback
feasibility